Stability of Evviva® Products
EVVIVA® products are tested to predict their bioavailability in the intestinal tract responsible for absorption with an in vitro method which consists of 3 enzymatic incubation steps.
The table shows how much active substance remains unabsorbed during the different stages of digestion, comparing EVVIVA® FULL OMEGA 3 (Microencapsulated) to a similar product protected with another system.
In phase T3, only 1.5% of the active substance in EVVIVA® FULL OMEGA 3 remains undigested while the rest was properly absorbed in the intestine. With other protection systems, up to 49% of active substance remains unabsorbed.
| STEP | Conc.% Of undigested active substance EVVIVA® FULL OMEGA 3 | Microencapsulated | Conc.% Of active substance UNDIGESTED | protected with other technologies |
|---|---|---|
| T0 | 100 | 100 |
| T1 | 59.2 | 72.7 |
| T2 | 27.2 | 59.6 |
| T3 | 1.5 | 49 |
Credits: Smart Mix